SMARCB1 is required for widespread BAF complex–mediated activation of enhancers and bivalent promotersRobert Nakayama, Cigall Kadoch, John L. Pulice et al.|Nature Genetics|2017Cited by 296
Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical OncologyEric P. Winer, Richard L. Schilsky, Julie R. Gralow et al.|Journal of Clinical Oncology|2008Cited by 290
The Wilms tumour gene WT1 is expressed in murine mesoderm–derived tissues and mutated in a human mesotheliomaSeon Ki Park, Daniel A. Haber, Martin Schalling et al.|Nature Genetics|1993Cited by 209
Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132Dian Wang, Burton Eisenberg, Qiang Zhang et al.|Annals of Surgical Oncology|2011Cited by 202
Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+)Michael C. Heinrich, Jonathan A. Fletcher, Jennifer Shoemaker et al.|Journal of Clinical Oncology|2005Cited by 64